RecruitingNot Applicable

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

United States75 participantsStarted 2021-04-01

Plain-language summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Currently using one or more topical glaucoma antihypertensives * Self-described symptoms of ocular surface discomfort * Xiidra is being prescribed as part of the subject's standard care Exclusion Criteria: * History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.), * current use of topical cyclosporine * current use of topical steroids * incisional ocular surgery within 6 months

What they're measuring

Change from baseline to week 12 in corneal fluorescein staining score

Timeframe: From baseline to Week 12

Change from baseline to week 12 in eye dryness score (EDS)

Timeframe: From baseline to Week 12

Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score

Timeframe: From baseline to Week 12

Trial details

NCT IDNCT04354545

SponsorUniversity of California, Los Angeles

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-01

Contact for this trial

Benjamin B Bert, MD

626-817-4701 BBert@mednet.ucla.edu

View on ClinicalTrials.gov More Glaucoma trials